- Trials with a EudraCT protocol (23)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
23 result(s) found for: Motor Coordination.
Displaying page 1 of 2.
EudraCT Number: 2020-003678-28 | Sponsor Protocol Number: AVXS-101-CL-102 | Start Date*: 2020-09-15 |
Sponsor Name:AveXis, Inc. | ||
Full Title: Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting but Non- Ambulatory Patients with Spinal Muscular Atrophy | ||
Medical condition: Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2009-010965-22 | Sponsor Protocol Number: NF1-SIMCODA | Start Date*: 2009-09-29 |
Sponsor Name:Erasmus MC - Department of Pediatrics | ||
Full Title: The effect of long-term simvastatin treatment on cognitive function and daily life in children with Neurofibromatosis 1: a one year randomized controlled trial | ||
Medical condition: Neurofibromatosis 1 | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-003784-30 | Sponsor Protocol Number: CHUBX2011/20 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:CHU de bordeaux | |||||||||||||
Full Title: Rubinstein-Taybi syndrome: approach to functional imaging and therapeutic trial | |||||||||||||
Medical condition: Rubinstein-Taybi Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004087-35 | Sponsor Protocol Number: AVXS-101-CL-304 | Start Date*: 2018-12-21 |
Sponsor Name:AveXis, Inc. | ||
Full Title: A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants with Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy with Multiple Copies of SMN2 | ||
Medical condition: Spinal Muscular Atrophy | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) IT (Completed) GB (GB - no longer in EU/EEA) BE (Completed) NL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-004731-76 | Sponsor Protocol Number: LTS16004 | Start Date*: 2019-04-18 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: Long-term extension safety and efficacy study of SAR442168 in participants with relapsing multiple sclerosis | |||||||||||||
Medical condition: Relapsing multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) CZ (Ongoing) EE (Ongoing) ES (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000618-32 | Sponsor Protocol Number: GNC-501 | Start Date*: 2022-09-29 | ||||||||||||||||
Sponsor Name:GENEURO SA | ||||||||||||||||||
Full Title: Temelimab as a Disease Modifying Therapy in Patients with Neurological, Neuropsychological, and Psychiatric (=Neuropsychiatric) Symptoms in Post-COVID-19 or Postacute Sequelae of COVID-19 (PASC) Sy... | ||||||||||||||||||
Medical condition: Postacute Sequelae of COVID-19 (PASC) Syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004997-23 | Sponsor Protocol Number: BN42358 | Start Date*: 2021-05-11 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASE | |||||||||||||
Medical condition: Early Parkinson's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) AT (Ongoing) IT (Ongoing) ES (Restarted) PL (Ongoing) LU (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019863-12 | Sponsor Protocol Number: Mouvements | Start Date*: Information not available in EudraCT |
Sponsor Name:Paris Descartes - Laboratoire Psychologie Clinique et Psychopathologie | ||
Full Title: Analyse du mouvement rythmique spontané, mesure de la cohérence cardiaque et appréciation des conduites cliniques et langagières chez des enfants hyperactifs en situation d'examen psychométrique et... | ||
Medical condition: Motor control and activities régulation attention's capacities | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-000182-31 | Sponsor Protocol Number: CHDR1438 | Start Date*: 2015-02-11 |
Sponsor Name:CHDR | ||
Full Title: A randomized, double-blind, placebo-controlled, cross-over study to assess the effects of fampridine on eye movements and nerve conduction in patients with multiple sclerosis (MS) and a unilateral ... | ||
Medical condition: Multiple sclerosis (MS) and a unilateral or bilateral internuclear ophthalmoplegia (INO) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002606-31 | Sponsor Protocol Number: TraumaPACT | Start Date*: 2019-04-04 | |||||||||||
Sponsor Name:Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg and its Commercial | |||||||||||||
Full Title: Sublingual versus intravenous Fentanyl in patients with acute trauma - a randomized, double-blind, double-dummy study to demonstrate non-inferiority TraumaPACT | |||||||||||||
Medical condition: Trauma with acute pain | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003231-29 | Sponsor Protocol Number: ATH434-201 | Start Date*: 2022-07-26 | |||||||||||
Sponsor Name:Alterity Therapeutics Limited | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in Multiple System Atrophy | |||||||||||||
Medical condition: Multiple System Atrophy (MSA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002822-10 | Sponsor Protocol Number: PL101-HD301 | Start Date*: 2020-12-11 | |||||||||||
Sponsor Name:Prilenia Neurotherapeutics Ltd. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients with Early Stage of Huntington Disease | |||||||||||||
Medical condition: Huntington Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) AT (Ongoing) FR (Ongoing) CZ (Ongoing) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001888-23 | Sponsor Protocol Number: TV7820-CNS-20002 | Start Date*: 2014-03-25 | |||||||||||
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc | |||||||||||||
Full Title: A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus... | |||||||||||||
Medical condition: Huntington’s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) NL (Completed) AT (Completed) PL (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000904-24 | Sponsor Protocol Number: TV7820-CNS-20016 | Start Date*: 2015-12-03 | |||||||||||
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc | |||||||||||||
Full Title: A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington’s Disease | |||||||||||||
Medical condition: Huntington's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Completed) AT (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003405-26 | Sponsor Protocol Number: NF1-EXCEL | Start Date*: 2014-09-03 | |||||||||||
Sponsor Name:Erasmus MC | |||||||||||||
Full Title: The effect of Lamotrigine on cognitive deficits associated with Neurofibromatosis type 1: a phase II randomized controlled multi-centre trial (NF1-EXCEL) | |||||||||||||
Medical condition: Neurofibromatosis type 1 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) BE (Ongoing) DK (Prematurely Ended) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000418-75 | Sponsor Protocol Number: TV5600-CNS-20007 | Start Date*: 2014-11-18 | |||||||||||
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | |||||||||||||
Full Title: A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients... | |||||||||||||
Medical condition: Huntington's Disease (HD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) GB (Completed) CZ (Completed) DE (Completed) PT (Completed) NL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005112-42 | Sponsor Protocol Number: C14-62 | Start Date*: 2015-06-22 | |||||||||||
Sponsor Name:INSERM | |||||||||||||
Full Title: A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3) | |||||||||||||
Medical condition: Huntington's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002163-17 | Sponsor Protocol Number: 15-138 | Start Date*: 2018-10-25 |
Sponsor Name:RWTH Aachen University represented by the Center for Translational & Clinical Research Aachen (CTC-A) | ||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICHS ATAXIA. | ||
Medical condition: Friedreich Ataxia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2009-013169-24 | Sponsor Protocol Number: PTC124-GD-008-DMD | Start Date*: 2010-01-19 | ||||||||||||||||
Sponsor Name:PTC Therapeutics Inc | ||||||||||||||||||
Full Title: A Phase 2a Study of Ataluren (PTC124) in Nonambulatory Patients with Nonsense–Mutation-Mediated Duchenne/Becker Muscular Dystrophy | ||||||||||||||||||
Medical condition: Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-003447-29 | Sponsor Protocol Number: DAP-PEDBAC-11-02 | Start Date*: 2013-06-11 | |||||||||||
Sponsor Name:Cubist Pharmaceuticals, Inc. | |||||||||||||
Full Title: A COMPARATIVE EVALUATION OF THE SAFETY AND EFFICACY OF DAPTOMYCIN VERSUS STANDARD OF CARE IN PEDIATRIC SUBJECTS TWO - SEVENTEEN YEARS OF AGE WITH BACTEREMIA CAUSED BY STAPHYLOCOCCUS AUREUS. | |||||||||||||
Medical condition: Bacteremia caused by Staphylococcus Aureus. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) ES (Completed) HU (Completed) GR (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.